Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peroxisomal trans-2-enoyl-CoA reductase (PECR)
- Target
- PECR
- Molecular classification
- Enzyme, Oxidoreductase
01
Overview
Peroxisomal trans-2-enoyl-CoA reductase (PECR) is a member of the short chain dehydrogenase/reductase (SDR) superfamily, localized primarily in peroxisomes, and plays a critical role in fatty acid metabolism. PECR catalyzes the reduction of trans-2-enoyl-CoA substrates of various chain lengths (typically C6:1–C16:1) using NADPH, with maximum activity seen for decenoyl-CoA (C10:1). It is integral to the chain elongation of fatty acids and the final step of converting trans-phytenoyl-CoA to phytanoyl-CoA during phytol degradation. PECR has been linked via genetic mapping to lung function and respiratory phenotypes, implying functional consequences in lipid metabolism for pulmonary physiology. Beyond its peroxisomal role, PECR has non-canonical functions in the endoplasmic reticulum, where it binds directly to the SERCA2b calcium pump and inhibits its activity, thus impacting intracellular calcium homeostasis
- Other names
- TERPSDR29C1PRO1004DCR-RPHSA2503032,4-dienoyl-CoA reductase-related proteinHPDHaseShort chain dehydrogenase/reductase family 29C member 1pVI-ARLDCRRPHPDHASEPVIARLTER
02
Mechanism of action
Hypothetical mechanisms for any future drugs could include: - Enzyme inhibition or activation to modulate fatty acid metabolism - Targeting peroxisomal β-oxidation pathways
03
Biological functions
Chain elongation of fatty acidsCatalyzes reduction of trans-2-enoyl-CoAs in fatty acid metabolismInvolved in phytol metabolic process and peroxisomal lipid metabolismImpacts ER calcium homeostasis by binding SERCA2b and suppressing its ATPase activity
04
Disease associations
Respiratory diseases, potential links to airway obstruction and lung functionBrugada Syndrome 2Ehlers-Danlos Syndrome, Hypermobility Type
05
Safety considerations
Although not documented for PECR-targeting drugs, therapeutic challenges may include altering lipid metabolism and affecting ER calcium homeostasis, which can impact cellular signaling and organ function
06
Interacting drugs
No approved or investigational drugs directly targeting PECR are currently listed in public genetic or pharmacological databases; indirect modulation through lipid metabolism or peroxisomal function may affect PECR activity
07
Biomarkers
No widely established biomarkers for patient selection or efficacy monitoring specific to PECR; genetic variants may be explored as candidate biomarkers for metabolic or respiratory conditions associated with altered PECR activity
Beyond the preview
Go deeper on Peroxisomal trans-2-enoyl-CoA reductase (PECR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peroxisomal trans-2-enoyl-CoA reductase (PECR).